π
|
Self-association of the Death Domains of the p55 Tumor Necrosis Factor (TNF) Receptor and Fas/APO1 Prompts Signaling for TNF and Fas/APO1 Effects (*)
7 auth.
M. Boldin,
I. Mett,
E. Varfolomeev,
I. Chumakov,
Y. Shemer-Avni,
J. Camonis,
...
D. Wallach
|
8 |
1995 |
8 π
|
π
|
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.
11 auth.
S. Trudel,
A. Stewart,
E. Rom,
E. Wei,
Zhi Hua Li,
Sarit Kotzer,
...
I. Chumakov,
Y. Singer,
Hong Chang,
S. Liang,
A. Yayon
|
7 |
2006 |
7 π
|
π
|
Human Combinatorial Fab Library Yielding Specific and Functional Antibodies against the Human Fibroblast Growth Factor Receptor 3*
19 auth.
Robert Rauchenberger,
E. Borges,
Elizabeth Thomassen-Wolf,
E. Rom,
R. Adar,
Y. Yaniv,
Michael Malka,
I. Chumakov,
Sarit Kotzer,
D. Resnitzky,
...
A. Knappik,
Silke Reiffert,
J. Prassler,
K. Jury,
D. Waldherr,
S. Bauer,
T. Kretzschmar,
A. Yayon,
C. Rothe
|
6 |
2003 |
6 π
|
π¬
|
Fibroblast Growth Factor 4 and Its Novel Splice Isoform Have Opposing Effects on the Maintenance of Human Embryonic Stem Cell SelfβRenewal
Yoav Mayshar,
E. Rom,
I. Chumakov,
Achia Kronman,
A. Yayon,
N. Benvenisty
|
6 |
2008 |
6 π¬
|
π
|
The inhibitory anti-FGFR 3 antibody , PRO-001 , is cytotoxic to t ( 4 ; 14 ) multiple myeloma cells
11 auth.
S. Trudel,
A. Stewart,
E. Rom,
E. Wei,
Zhi Hua Li,
Sarit Kotzer,
...
I. Chumakov,
Y. Singer,
Hong Chang,
S. Liang,
A. Yayon
|
3 |
2006 |
3 π
|
π
|
Targeting FGFR3 in t(4;14) Mutiple Myeloma: Pre-Clinical Studies of PRO-001, a Novel Anti-FGFR3 Neutralizing Antibody.
11 auth.
S. Trudel,
E. Wei,
Zhi Hua Li,
E. Rom,
I. Chumakov,
Y. Singer,
...
C. Chen,
D. Reece,
J. Mikhael,
A. Stewart,
A. Yayon
|
0 |
2004 |
0 π
|
π
|
FGF4 And its Novel Splice Isoform Have Opposing Effects on the Maintenance of Human Embryonic Stem Cell Self Renewal
7 auth.
Yoav Mayshar,
E. Rom,
I. Chumakov,
Achia Kronman,
A. Yayon,
Nissim,
...
Benvenisty
|
0 |
2008 |
0 π
|
π’
|
V.A. Kostitsin Eco-Genetic Model in Studying the Race Dynamics of the Multirakered Muksun of the Yenisei River
N. Haydenok,
V. Chumakov,
I. Chumakov
|
0 |
2021 |
0 π’
|